Business Parks & Science Centres

 
 
 

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 2927 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Catalent–Leonard Green & Partners: investment, 201904– up to $1b convertible preferred stock with $650m issued 2019-04-15
Paragon Bioservices–Catalent: investment, 201904– acquisition 100% for $1.2b in cash on cash-free + debt-free basis 2019-04-15
Uniqure–HC Wainwright: investor conference, 201904 supply service Uniqure attends HC Wainwright Global Life Sciences Conference in London 2019-04-09
Celyad–HC Wainwright: investor conference, 201904 supply service Celyad presents at HC Wainwright Global Life Sciences Conference in London 2019-04-08
4SC–HC Wainwright: investor conference, 201904 supply service 4SC presents at HC Wainwright Global Life Sciences Conference in London 2019-04-07
AgomAb Therapeutics–Instinctif Partners: public relations, 201901 service existent by Instinctif für UK + RoW 2019-04-03
Cambridge Innovation Capital–SEVERAL: investment, 201904 financing round £150m with Univ Cambridge as cornerstone investor 2019-04-01
Cambridge Innovation Capital–Univ Cambridge: investment, 201904 financing round totalling £150m incl cornerstone investor Univ Cambridge 2019-04-01
Karuna–PureTech Health: investment, 201903–201904 financing round Series B totalling $80m incl exisiting investor PureTech Health 2019-04-01
Karuna–SEVERAL: investment, 201903–201904 financing round Series B $80m led by ARCH Venture Partners incl $5m debt conversion 2019-04-01
Karuna–Wellcome Trust: investment, 201903–201904 financing round Series B totalling $80m incl exisiting investor Wellcome Trust 2019-04-01
Mogrify–United Kingdom (govt): grant, 201904 SBRI Healthcare funding for developm of cell therapy for osteoarthritis 2019-04-01
Cellnovo–NONE: investment, 201903 in administration 2019-03-28
Inivata–Consilium: public relations, 201903 service existent by CSC 2019-03-28
Inivata–LifeSci: public relations, 201903 service existent IR by LifeSci Advisors 2019-03-28
Univ College London–ArcherDx: PCR technology, 201903– collab €na use of AMP technology in UCL-sponsored UK lung cancer diagnostics TRACERx study 2019-03-28
United Kingdom (govt)–Cambridge Cancer Genomics: personalised immuno-oncology, 201903– collab long-term of Genomics England + CCG.ai 2019-03-21
Verona Pharma–Novo Group: investment, 201903 existent investment Novo Holdings owns 11.76% shareholding in Verona Pharma plc 2019-03-21
NeoPhore–Optimum Strategic Communications: public relations, 201903 service existent by Optimum 2019-03-20
Oncimmune–Consilium: public relations, 201903 service existent by CSC 2019-03-19
Oncimmune–Qiagen: investment, 201903 up to 1.34% shareholding for Qiagen after Oncimmune’s acquisition of Protagen 2019-03-19
Protagen–Oncimmune: investment, 201903 acquisition of Portagen for up to £4.11m in up to 2.636m ordinary shares 2019-03-19
Mogrify–United Kingdom (govt): grant, 201903 Innovate UK funding £420k to use big data analysis to advance cell therapies 2019-03-18
Metrion Biosciences–o2h: investment, 201903 financing round incl o2h Ventures Therapeutics Fund 2019-03-14
Metrion Biosciences–SEVERAL: investment, 201903 financing round incl o2h Ventures Therapeutics Fund 2019-03-14
Rocket Pharmaceuticals–MolMed: gene therapy, 201903– collab expansion developm + manufacture of lentiviral vectos by MolMed for three new indications 2019-03-13
MeiraGTx–Barclays: investor conference, 201903 supply service MeiraGTx presents at Barclays Global Healthcare Conference 2019-03-12
Oxford BioMedica–Microsoft: bioinformatics, 201903–202102 collab r+d using MS Azure cloud + machine learing to optimise gene therapy vectors 2019-03-12
AstraZeneca–Seres Therapeutics: microbiomics, 201903–202202 collab research 3y $20m + research funding for microbiomics to support I-O therapies 2019-03-11
Orchard Therapeutics–Cowen: investor conference, 201903 supply service Orchard presents at Cowen & Co Annual Health Care Conference 2019 2019-03-11
Nightstar Therapeutics–Biogen: investment, 201903– acquisition $877m in cash at $25.5/share ANNOUNCED 2019-03-04
iOnctura–Optimum Strategic Communications: public relations, 201902 service existent by Optimum 2019-02-28
JnJ–AdoRx: adenosine receptor antagonists, 201902– collab developm + excl option €na lung cancer drugs with JnJ Innovation 2019-02-28
CN Innovations–MIT: organ-on-a-chip technology, 201902– license excl for organ-on-a-chip with human tissues fomr up to 10 organs for CN Bio 2019-02-27
MeiraGTx–683 Capital Management: investment, 201902 private placement totalling $80m incl co-investor 683 Capital Management 2019-02-27
MeiraGTx–JnJ: investment, 201902 private placement totalling $80m incl $40m from lead investor JJDC Inc 2019-02-27
MeiraGTx–Orbimed: investment, 201902 private placement totalling $80m incl co-investor Orbimed Advisors 2019-02-27
MeiraGTx–Perceptive Advisors: investment, 201902 private placement totalling $80m incl co-investor Perceptive Advisors 2019-02-27
MeiraGTx–SEVERAL: investment, 201902 private placement $80m with 5.8m ordinary shares at $13.8/share led by JJDC Inc 2019-02-27
Anaveon–Novartis: investment, 201902 financing round Series A totalling CHF35m incl co-investor Novartis Venture Fund 2019-02-26
Anaveon–SEVERAL: investment, 201902 financing round Series A CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
Anaveon–Wellcome Trust: investment, 201902 financing round Series A totalling CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
General Electric–Danaher: investment, 201902– acquisition $21.4b in cash of biopharma business of GE Life Sciences ANNOUNCED 2019-02-25
Ynsect–SEVERAL: investment, 201902 financing round Series C €110m ($1245m) led by Astanor Ventures 2019-02-21
Danaher–Barclays: investor conference, 201902 supply service Danaher presents at Barclays Industrial Select Conference in Miami 2019-02-20
Mogrify–24Haymarket: investment, 201902 seed financing round totalling $3.7m incl co-investor 24Haymarket 2019-02-20
Mogrify–Ahren Innovation Capital: investment, 201902 seed financing round totalling $3.7m incl existing + lead investor Ahren Innovation Capital 2019-02-20
Mogrify–PERSON: investment, 201902 seed financing round totalling $3.7m incl co-investor Darrin M Disley 2019-02-20
Mogrify–SEVERAL: investment, 201902 seed financing round $3.7m led by Ahren Innovation Capital + incl 24Haymarket + Darrin Disley 2019-02-20
Mogrify–Zyme Communications: public relations, 201902 service existent by Zyme 2019-02-20
Sygnature Discovery–BioStrata: public relations, 201902 service existent by BioStrata 2019-02-15
Grey Wolf Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Grey Wolf Therapeutics–Canaan Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Grey Wolf Therapeutics–Consilium: public relations, 201902 service existent by CSC 2019-02-11
Grey Wolf Therapeutics–SEVERAL: investment, 201902 financing round Series A £10m with Andera Partners + Canaan 2019-02-11
Pathios Therapeutics–Sygnature Discovery: drug discovery services, 201902– collab service discovery for GPCR target in autoimmune diseases + cancer 2019-02-07
United Kingdom (govt)–Qiagen: bioinformatics, 201902– supply Genomics England selects QCI for genome sequencing project of NHS 2019-02-04
Apceth–Hitachi: investment, 201901–201904 acquisition €75.5m 100% of Apceth Biopharma GmbH from Apceth GmbH by Hitachi Chemical 2019-01-31
JnJ–MeiraGTx: gene therapy, 201901– collab r+d + license ww excl $100m upfront + milestones + funding + 20% royalties for inherited retinals diases 2019-01-31
Horizon Discovery–Rutgers Univ: gene editing technology, 201901– collab strategic developm + excl license option for base editing technology 2019-01-28
Wren Therapeutics–Baupost Group: investment, 201901 financing round Series A totalling £18m including lead investor The Baupost Group 2019-01-22
Wren Therapeutics–LifeForce Capital: investment, 201901 financing round Series A totalling £18m including co-investor LifeForce Capital 2019-01-22
Wren Therapeutics–SEVERAL: investment, 201901 financing round Series A £18m from Baupost Group + LifeForce Capital + high net worth individuals 2019-01-22
ATUM–Solentim: cell line development technology, 201901– collab product integration of VIPS hardware + Leap-In Transposase expression technology 2019-01-14
Solentim–Sciad Communications: public relations, 201901 service existent by Sciad 2019-01-14
Chronomics–SEVERAL: investment, 201901 seed financing round £1.12m from Anthemis + SOSV 2019-01-10
Orchard Therapeutics–JPMorgan Chase: investor conference, 201901 supply service Orchard presents at JP Morgan Healthcare Conference 2019 2019-01-09
AstraZeneca–Aptamer Group: aptamer drug conjugates, 201901– collab research to enable drug delivery to the kidney 2019-01-07
Exscientia–Celgene: investment, 201901 financing round Series B totalling $26m incl new investor Celgene Corp 2019-01-07
Exscientia–Evotec: investment, 201901 financing round Series B totalling $26m incl $6m from existing investor Evotec AG 2019-01-07
Exscientia–GT Healthcare Capital Partners: investment, 201901 financing round Series B totalling $26m incl new investor GT Healthcare Capital Partners 2019-01-07
Exscientia–SEVERAL: investment, 201901 financing round Series B $26m incl Celgene Corp + GT Heallthcare Capital Partners + Evotec 2019-01-07
F2G Ltd–Optimum Strategic Communications: public relations, 201901 service existent by Optimum 2019-01-07
Sophia Genetics–Alychlo: investment, 201901 financing round totalling $77m incl existing + co-investor Alychlo 2019-01-04
Sophia Genetics–Balderton Capital: investment, 201901 financing round totalling $77m incl existing + co-investor Balderton Capital 2019-01-04
Sophia Genetics–Generation Investment Management: investment, 201901 financing round totalling $77m incl new + lead investor Generation 2019-01-04
Sophia Genetics–Idinvest Partners: investment, 201901 financing round totalling $77m incl new + co-investor Idinvest Partners 2019-01-04
Sophia Genetics–SEVERAL: investment, 201901 financing round $77m incl new + lead investor Generation Investment Management LLP 2019-01-04
Confo Therapeutics–Instinctif Partners: public relations, 201901 service existent by Instinctif for international media 2019-01-03
Fujifilm–Zyme Communications: public relations, 201901 service existent for Fujifilm Irvine Scientific by Zyme 2019-01-02
CARB-X–Germany (govt): grant, 201901–202212 BMBF commits €40m over 4 years 2019-01-01
Procarta Biosystems–Novo Group: investment, 2018 investment €1.5m by Novo REPAIR Impact Fund 2018-12-31
Vedanta Biosciences–BMS: investment, 201812 financing round Series C totalling $27m incl new investor BMS 2018-12-24
Vedanta Biosciences–BPCE: investment, 201812 financing round Series C totalling $27m incl existing investor Seventure Partners 2018-12-24
Vedanta Biosciences–Gates Foundation: investment, 201812 financing round Series C totalling $27m incl new investor Gates Foundation 2018-12-24
Vedanta Biosciences–Invesco: investment, 201812 financing round Series C totalling $27m incl existing investor Invesco Asset Management 2018-12-24
Vedanta Biosciences–PureTech Health: investment, 201812 financing round Series C totalling $27m incl existing investor PureTech Health 2018-12-24
Vedanta Biosciences–Rock Springs Capital: investment, 201812 financing round Series C totalling $27m incl existing investor Rock Springs Capital 2018-12-24
Vedanta Biosciences–SEVERAL: investment, 201812 financing round Series C $27m Gates + BMS + Rock Springs Capital + Invesco + Seventure + PureTech 2018-12-24
Nabriva–Hercules Technology: credit, 201812–202306 term loan up to $75m with $25m up front von Hercules Capital 2018-12-21
Morphogen-IX–Cambridge Innovation Capital: investment, 201812 financing round Series B totalling £18.4m incl existing + co-investor CIC 2018-12-20
Morphogen-IX–Medicxi Ventures: investment, 201812 financing round Series B totalling £18.4m incl existing + lead investor Medicxi 2018-12-20
Morphogen-IX–SEVERAL: investment, 201812 financing round Series B £18.4m ($23.2m) led by Medicxi + incl CIC + Cambridge Enterprise 2018-12-20
Morphogen-IX–Univ Cambridge: investment, 201812 financing round Series B totalling £18.4m incl existing + co-investor Cambridge Enterprise 2018-12-20
Cambridge Cancer Genomics–SEVERAL: investment, 201812 seed financing round $4.5m incl AME Cloud Ventures + Y Combinator et al. 2018-12-18
Orchard Therapeutics–Sirion Biotech: gene therapy manufacturing technology, 201812– license for stem cell gene therapies 2018-12-14
Lonza–ERS Genomics: CRISPR technology, 201812– license €na for bioproduction products + services + iPSC research to Lonza Pharma & Biotech 2018-12-13
Synthace–SEVERAL: investment, 201812 financing round Series B $25.6m led by Horizons Ventures 2018-12-12
AstraZeneca–Cancer Research UK: functional genomics, 201812– collab establishment of joint venture Functional Genomics Centre in Cambridge 2018-12-10
Genomics plc–F-Prime: investment, 201812 financing round Series B 2nd closing totalling £8m from Foresite Capital + F-Prime Capital 2018-12-10
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top